ImmuCell (NASDAQ:ICCC) Shares Pass Above 200 Day Moving Average – Here’s What Happened

ImmuCell Co. (NASDAQ:ICCC) shares passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $4.99 and traded as high as $6.65. ImmuCell shares last traded at $6.52, with a volume of 20,435 shares trading hands.

ImmuCell Trading Up 5.5%

The firm has a market cap of $58.92 million, a P/E ratio of -13.04 and a beta of 0.23. The company has a debt-to-equity ratio of 0.36, a current ratio of 3.11 and a quick ratio of 1.44. The stock has a 50 day moving average of $5.30 and a 200 day moving average of $4.99.

ImmuCell (NASDAQ:ICCC) last released its earnings results on Wednesday, May 14th. The biotechnology company reported $0.16 EPS for the quarter. ImmuCell had a negative return on equity of 15.32% and a negative net margin of 15.99%. The business had revenue of $8.07 million for the quarter.

Hedge Funds Weigh In On ImmuCell

Several institutional investors and hedge funds have recently bought and sold shares of ICCC. Mesirow Financial Investment Management Inc. grew its position in ImmuCell by 100.0% during the 4th quarter. Mesirow Financial Investment Management Inc. now owns 24,356 shares of the biotechnology company’s stock worth $125,000 after acquiring an additional 12,178 shares during the last quarter. Geode Capital Management LLC grew its position in ImmuCell by 13.9% during the 4th quarter. Geode Capital Management LLC now owns 64,538 shares of the biotechnology company’s stock worth $332,000 after acquiring an additional 7,878 shares during the last quarter. Dauntless Investment Group LLC bought a new position in ImmuCell during the 4th quarter worth approximately $676,000. Northern Trust Corp grew its position in ImmuCell by 51.0% during the 4th quarter. Northern Trust Corp now owns 44,374 shares of the biotechnology company’s stock worth $229,000 after acquiring an additional 14,982 shares during the last quarter. Finally, Citadel Advisors LLC bought a new position in ImmuCell during the 4th quarter worth approximately $149,000. 13.47% of the stock is currently owned by institutional investors.

About ImmuCell

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E.